Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 43 44 15 33


External Ids:

Disease Ontology 12 DOID:2089
ICD9CM 35 564.0 564.00
MeSH 44 D003248
NCIt 50 C37930
SNOMED-CT 68 14760008
ICD10 33 K59.0 K59.00
UMLS 72 C0009806

Summaries for Constipation

MedlinePlus : 43 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to intestinal pseudo-obstruction and intestinal obstruction. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ondansetron and Cyclobenzaprine have been mentioned in the context of this disorder. Affiliated tissues include colon, breast and lung, and related phenotypes are no effect and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 75 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
# Related Disease Score Top Affiliating Genes
1 intestinal pseudo-obstruction 33.3 SST RET FLNA
2 intestinal obstruction 33.1 RET MLN GDNF FLNA
3 hypoganglionosis 33.1 RET GDNF
4 irritable bowel syndrome 32.7 VIP TAC1 SLC6A4 PYY MLN HTR4
5 diarrhea 32.2 SST HTR3A CCK
6 megacolon 32.0 VIP RET GDNF
7 gastroesophageal reflux 31.4 VIP PYY MLN CCK
8 dyspepsia 31.3 SST SLC6A4 HTR3A CCK
9 anismus 31.3 VIP TAC1
10 pain agnosia 31.3 TAC1 OPRM1 CCK
11 achalasia 31.3 VIP RET KIT
12 gastroparesis 31.2 MLN HTR3A CCK
13 functional diarrhea 31.1 TAC1 HTR4 HTR3A
14 multiple endocrine neoplasia 31.0 RET GDNF CALCA
15 colonic pseudo-obstruction 31.0 SST MLN KIT HTR4
16 eating disorder 30.8 SLC6A4 PYY CCK
17 gastrointestinal system disease 30.8 SST PYY MLN KIT HTR4 CCK
18 carcinoid syndrome 30.8 SST PYY HTR3A CALCA
19 multiple endocrine neoplasia, type iib 30.7 RET GDNF CALCA
20 functional colonic disease 30.5 SST MLN KIT HTR4
21 neuroma 30.4 RET GDNF CALCA
22 pheochromocytoma 30.3 VIP SST RET GDNF CALCA
23 pertussis 30.3 VIP SST OPRM1
24 anorexia nervosa 30.2 SLC6A4 PYY CCK
25 panic disorder 30.2 SLC6A4 HTR3A CCK
26 serotonin syndrome 30.0 TAC1 SST SLC6A4 PYY HTR3A
27 alcohol dependence 29.9 SLC6A4 OPRM1 HTR3A CCK
28 migraine with or without aura 1 29.8 VIP TAC1 SLC6A4 PPOX HTR3A CALCA
29 outlet dysfunction constipation 12.4
30 coarse face hypotonia constipation 12.2
31 opitz-kaveggia syndrome 11.6
32 hirschsprung disease 1 11.6
33 porphyria 11.5
34 pitt-hopkins syndrome 11.5
35 hashimoto thyroiditis 11.5
36 sacral defect with anterior meningocele 11.5
37 parkinson disease, late-onset 11.4
38 bartter disease 11.4
39 fg syndrome 2 11.4
40 hemorrhoid 11.3
41 hypothyroidism 11.3
42 colorectal cancer 11.3
43 neurogenic bowel 11.3
44 intestinal volvulus 11.3
45 celiac disease 1 11.3
46 peritonitis 11.3
47 diverticulitis 11.3
48 appendicitis 11.3
49 chronic intestinal pseudoobstruction 11.3
50 primary hyperparathyroidism 11.2

Graphical network of the top 20 diseases related to Constipation:

Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AQP3 CALCA CCK CLCN2 COL17A1 FLNA
2 Decreased viability GR00381-A-1 9.61 HTR3A MLN SLC6A4
3 Decreased viability GR00381-A-3 9.61 HTR3A MLN SLC6A4
4 Decreased viability GR00402-S-2 9.61 HTR3A MLN SLC6A4

MGI Mouse Phenotypes related to Constipation:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 AQP3 CLCN2 FLNA GDNF HTR3A HTR4
2 homeostasis/metabolism MP:0005376 10.28 AQP3 CCK CLCN2 FLNA HTR3A HTR4
3 growth/size/body region MP:0005378 10.17 AQP3 FLNA GDNF HTR3A HTR4 KIT
4 cardiovascular system MP:0005385 10.15 AQP3 CLCN2 FLNA GDNF KIT RET
5 digestive/alimentary MP:0005381 10.13 AQP3 CLCN2 FLNA GDNF KIT OPRM1
6 mortality/aging MP:0010768 10.13 AQP3 FLNA GDNF HTR3A HTR4 KIT
7 endocrine/exocrine gland MP:0005379 10.11 CCK CLCN2 GDNF HTR3A KIT OPRM1
8 immune system MP:0005387 10.07 AQP3 CLCN2 FLNA GDNF HTR3A KIT
9 nervous system MP:0003631 10.07 CCK CLCN2 FLNA GDNF HTR3A HTR4
10 normal MP:0002873 9.81 FLNA KIT OPRM1 PYY RET SLC6A4
11 renal/urinary system MP:0005367 9.56 AQP3 CCK GDNF HTR3A KIT PPOX
12 respiratory system MP:0005388 9.17 AQP3 FLNA HTR4 KIT NALCN RET

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 673)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Ondansetron Approved Phase 4 99614-02-5 4595
Cyclobenzaprine Approved Phase 4 303-53-7 2895
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
Orphenadrine Approved Phase 4 83-98-7 4601
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
Linaclotide Approved Phase 4 851199-59-2 65351
Sorbitol Approved Phase 4 50-70-4 5780
Methadone Approved, Illicit Phase 4 76-99-3 4095
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
Metronidazole Approved Phase 4 443-48-1 4173
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
Topiramate Approved Phase 4 97240-79-4 5284627
21 Apricot Approved Phase 4
Metformin Approved Phase 4 657-24-9 4091 14219
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
Gliclazide Approved Phase 4 21187-98-4 3475
Dihydrocodeine Approved, Illicit Phase 4 125-28-0
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Labetalol Approved Phase 4 36894-69-6 3869
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
Remifentanil Approved Phase 4 132875-61-7 60815
Propranolol Approved, Investigational Phase 4 525-66-6 4946
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Ferrous succinate Approved Phase 4 10030-90-7
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-61-2, 135729-56-5 148211
4-Aminopyridine Approved Phase 4 504-24-5 1727
Lactulose Approved Phase 4 4618-18-2 11333
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
tannic acid Approved Phase 4 1401-55-4
Alvimopan Approved, Investigational Phase 4 156053-89-3 5488548
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Magnesium oxide Approved Phase 4 1309-48-4 14792
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
Ibuprofen Approved Phase 4 15687-27-1 3672
Magnesium citrate Approved Phase 4 3344-18-1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029

Interventional clinical trials:

(show top 50) (show all 1469)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
2 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
3 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
4 The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial Unknown status NCT01388712 Phase 4
5 An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study Unknown status NCT03148002 Phase 4 Current Bowel Protocol (senna/lactulose);PEG Bowel Protocol (PEG/lactulose)
6 Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes Unknown status NCT02949882 Phase 4
7 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study Unknown status NCT01779765 Phase 4
8 Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal fissure in Children Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
9 Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study. Unknown status NCT03177434 Phase 4 polyethylene glycols (PEG) 3350;Lactulose Oral Product
10 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
11 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of MiraLAX (PEG 3350) vs Golytely as Bowel Preparation for Screening Colonoscopy Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
12 Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy Unknown status NCT02781493 Phase 4 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen;2 mg Placebo plus 2 L Polyethylene Glycol regimen
13 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
14 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
15 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Unknown status NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
16 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men Unknown status NCT02361502 Phase 4 mirabegron;placebo
17 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
18 Randomized Placebo Controlled Trial of Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair Unknown status NCT02992028 Phase 4 Intravenous Nutrition (Vitamins) injection;Intravenous Saline injection
19 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
20 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
21 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
22 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
23 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
24 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
25 An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
26 Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial Unknown status NCT02680626 Phase 4 Magnesium Sulfate;Ropivacaine
27 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
28 Recurrent Urinary Tract Infections in Children: Bacterial Identification, Antibiotic Susceptibility Profiling and Cytokine Levels Associated With Antibiotic Prophylaxis Unknown status NCT02357758 Phase 4 Antibiotic Prophylaxis
29 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
30 Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy Unknown status NCT02803788 Phase 4 ramosetron, ondansetron, dexamethasone
31 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
32 Sacral Nerve Stimulation for Anal Incontinence and Bowel Control Completed NCT00200005 Phase 4
33 A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
34 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
35 Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation Completed NCT01460225 Phase 4 lubiprostone
36 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
37 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
38 A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
39 An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients Completed NCT00164125 Phase 4 polyethyleneglycol3350
40 A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
41 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
42 A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children Completed NCT00583609 Phase 4 PEG3350
43 Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation Completed NCT00672139 Phase 4 Methylnaltrexone bromide
44 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
45 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone
46 Tolerance of Long Term Administration of Forlax® 10g in Elderly Ambulatory or Institutionalized Patients Suffering From Chronic Constipation. Single Blind Randomised Lactulose-controlled Study With Individual Expected Benefit. Completed NCT00276354 Phase 4 PEG 4000 (Forlax ®)
47 A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation Completed NCT02837783 Phase 4 Linaclotide;Placebo
48 Investigation of Dried Plums in the Treatment of Adults With Constipation Completed NCT01180725 Phase 4
49 A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation Completed NCT00712543 Phase 4 lactulose (Kristalose®);liquid lactulose
50 A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation. Completed NCT00770432 Phase 4 Polyethylene glycol 3350

Search NIH Clinical Center for Constipation

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Magnesium hydroxide
Magnesium sulfate
Polyethylene glycol
Sodium lauryl sulfoacetate
Sodium phosphate, monobasic, unspecified form

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

Colon, Breast, Lung, Testes, Spinal Cord, Prostate, Liver

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 22412)
# Title Authors PMID Year
Use of prucalopride in adults with chronic idiopathic constipation. 38 17
31096799 2019
There might be a distinctive clinical phenotype of constipation with non-cardiac chest pain which responds to combination laxatives: A retrospective, longitudinal symptom analysis. 38 17
31261496 2019
Effectiveness and safety of lactobacilli in children with functional constipation: Study protocol for a meta-analysis and systematic review. 38 17
31096503 2019
Study of the aqueous extract of Aloe vera and its two active components on the Wnt/β-catenin and Notch signaling pathways in colorectal cancer cells. 38
31319122 2019
Systematic review: sacral nerve stimulation in the treatment of constipation and fecal incontinence in children with emphasis in anorectal malformation. 38
31256299 2019
Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension. 38
31011797 2019
Nonpain Symptom Management. 38
31375185 2019
Redundant: A case of complicated dolichocolon in a neonate. 38
31360279 2019
Sleep quality with WHO Step III opioid use for cancer pain. 38
30018128 2019
Development of an UHPLC-MS/MS method for comparative pharmacokinetics of nine anthraquinones in rats and application to dosage conversion between different Semen Cassiae forms. 38
31288192 2019
Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects. 38
30351180 2019
Successful Colonoscopy-assisted Cecostomy Tube Replacement to Salvage Lost Cecostomy Tract Access in Children. 38
31169658 2019
Pure autonomic failure presenting as Harlequin syndrome. 38
31331696 2019
Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. 38
31320277 2019
Medium-term outcome of laparoscopic sacrocolpopexy using polivinylidene fluoride as compared to a hybrid polyglecaprone and polypropylene mesh: A matched control study. 38
31290173 2019
Jejunal Diverticulitis: A Single-Center Experience and Proposed Management Algorithm. 38
31066632 2019
Weeding Out the Problem: The Impact of Preoperative Cannabinoid Use on Pain in the Perioperative Period. 38
31425232 2019
Successful Management of a Giant Anterior Sacral Meningocele Associated with Low-Dysplastic Spondylolisthesis from a Single Posterior Approach: Case Report. 38
31009790 2019
Bladder and bowel dysfunction, adaptive behaviour and psychiatric profiles in adults affected by autism spectrum disorders. 38
31270838 2019
Constipation, antiepileptic drugs, and gingivitis in children and adolescents with cerebral palsy. 38
30817037 2019
Effect of acupressure on constipation in patients with advanced cancer. 38
30675666 2019
Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. 38
31115923 2019
Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. 38
31274696 2019
Time to treatment response of a magnesium- and sulphate-rich natural mineral water in functional constipation. 38
31170680 2019
MRI analysis of fecal volume and dryness: Validation study using an experimental oxycodone-induced constipation model. 38
30609164 2019
Probiotics and constipation: mechanisms of action, evidence for effectiveness and utilisation by patients and healthcare professionals - ERRATUM. 38
31366410 2019
Opioid induced constipation management in orthopaedic and trauma patients: treatment and the potential of nurse-initiated management. 38
31126838 2019
Development of a Patient-reported Experience and Outcome Measures in Pediatric Patients Undergoing Bowel Management for Constipation and Fecal Incontinence. 38
30921256 2019
Lower dietary fibre intake, but not total water consumption, is associated with constipation: a population-based analysis. 38
31087475 2019
4,8-Dimethylcoumarin inhibitors of intestinal anion exchanger slc26a3 (down-regulated in adenoma, DRA) for anti-absorptive therapy of constipation. 38
31389695 2019
Assessing the efficacy of peripherally acting µ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. 38
29980606 2019
Sacral nerve stimulation with appropriate parameters improves constipation in rats by enhancing colon motility mediated via the autonomic-cholinergic mechanisms. 38
31411502 2019
Usefulness of ultrasonographic evaluation of stool and/or gas distribution for the treatment strategy of chronic constipation. 38
31406924 2019
Comparison of clinical effectiveness of nurse led care among Chinese patients with cancer: A prospective study evaluating effective patient care compared to consultant oncologist. 38
31387796 2019
Effect of Royal Jelly on Mouse Isolated Ileum and Gastrointestinal Motility. 38
31329014 2019
[Obstructed Defecation: Relevance of Sacral Neuromodulation]. 38
31412417 2019
Physicochemical properties and laxative effects of polysaccharides from Anemarrhena asphodeloides Bge. in loperamide-induced rats. 38
31102614 2019
Gut Environment and Dietary Habits in Healthy Japanese Adults and their Association with Bowel Movement. 38
31434096 2019
Postoperative pain following Descemet membrane endothelial keratoplasty (DMEK): a prospective study. 38
31399786 2019
Ectopic adrenocorticotrophic hormone syndrome (EAS) with phaeochromocytoma: a challenging endocrine case with a happy ending. 38
31434676 2019
Agonist-dependent development of delta opioid receptor tolerance in the colon. 38
30904952 2019
Systematic Review and Meta-Analysis on Using Acupressure to Promote the Health of Older Adults. 38
31426687 2019
Intrathecal baclofen trial using a temporary indwelling intrathecal catheter - A single institution experience. 38
31400999 2019
Acute abdominal pain due to internal herniation of the sigmoid colon, fallopian tube and left ovary, a rare presentation of Allen Masters syndrome. 38
29433380 2019
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. 38
30460505 2019
The Impact of Alvimopan on Return of Bowel Function After Major Spine Surgery - A Prospective, Randomized, Double-Blind Study. 38
30951602 2019
Home enteral nutrition for infants after gastrointestinal surgery. 38
31221286 2019
Daikenchuto, a traditional Japanese herbal medicine, promotes colonic transit by inducing a propulsive movement pattern. 38
31374154 2019
Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. 38
30733264 2019
Factors Associated With Use of Nonoral Nutrition and Hydration Support in Adult Patients With Postural Tachycardia Syndrome. 38
30561086 2019

Variations for Constipation

ClinVar genetic disease variations for Constipation:

# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PPOX NM_001122764.3(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 1:161140885-161140885 1:161171095-161171095
2 RET NM_020630.5(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 10:43617416-43617416 10:43121968-43121968
3 46;XX;t(7;13)(p13;q34)dn Translocation Pathogenic
4 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
5 46;XX;t(19;21)(q13.3;q22.3)dn Translocation Pathogenic
6 COL17A1 NM_000494.4(COL17A1): c.4143_4144AG[1] (p.Glu1382fs) short repeat Pathogenic 10:105793710-105793714 10:104033953-104033956
7 Translocation Likely pathogenic
8 MT-TP ; MT-TT m.15923A> G single nucleotide variant Conflicting interpretations of pathogenicity rs1556424691 MT:15923-15923 MT:15923-15923
9 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 6:157520041-157520041 6:157198907-157198907
10 LSM1 NM_014462.3(LSM1): c.231+4A> C single nucleotide variant Uncertain significance rs775468919 8:38027316-38027316 8:38169798-38169798

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 SLC6A4 RET OPRM1 KIT HTR4 HTR3A
2 extracellular region GO:0005576 9.85 VIP TAC1 SST PYY MLN GDNF
3 cell-cell junction GO:0005911 9.67 KIT FLNA COL17A1 AQP3
4 perikaryon GO:0043204 9.63 VIP OPRM1 CCK
5 integral component of presynaptic membrane GO:0099056 9.58 SLC6A4 OPRM1 HTR3A
6 integral component of postsynaptic membrane GO:0099055 9.5 SLC6A4 OPRM1 HTR3A
7 axon GO:0030424 9.35 TAC1 RET OPRM1 HTR3A CCK
8 neuronal cell body GO:0043025 9.1 TAC1 SST RET HTR3A FLNA CCK
9 plasma membrane GO:0005886 10.21 TAC1 SLC6A4 RET OPRM1 NALCN KIT

Biological processes related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.73 SST SLC6A4 RET PPOX
2 chemical synaptic transmission GO:0007268 9.62 TAC1 SST HTR4 HTR3A
3 negative regulation of apoptotic process GO:0043066 9.58 VIP GDNF FLNA
4 mRNA stabilization GO:0048255 9.46 VIP GDNF
5 regulation of sensory perception of pain GO:0051930 9.43 VIP OPRM1 CCK
6 enteric nervous system development GO:0048484 9.37 RET GDNF
7 neuropeptide signaling pathway GO:0007218 9.33 TAC1 PYY OPRM1
8 G protein-coupled receptor signaling pathway GO:0007186 9.28 VIP TAC1 SST PYY OPRM1 MLN
9 response to pain GO:0048265 8.96 TAC1 RET

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.26 SLC6A4 HTR3A
2 peptide hormone receptor binding GO:0051428 9.16 VIP CCK
3 neuropeptide hormone activity GO:0005184 9.13 VIP PYY CCK
4 hormone activity GO:0005179 9.1 VIP SST PYY MLN CCK CALCA

Sources for Constipation

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....